SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 27 filers reported holding SYNDAX PHARMACEUTICALS INC in Q1 2016. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $5,824,000 | -10.6% | 497,801 | +6.7% | 0.07% | -18.5% |
| Q2 2017 | $6,516,000 | -5.9% | 466,427 | -7.6% | 0.08% | -13.8% |
| Q1 2017 | $6,924,000 | +262.9% | 504,697 | +89.6% | 0.09% | +213.3% |
| Q4 2016 | $1,908,000 | -73.1% | 266,164 | -43.1% | 0.03% | -76.7% |
| Q3 2016 | $7,087,000 | +316.9% | 467,461 | +170.8% | 0.13% | +279.4% |
| Q2 2016 | $1,700,000 | -14.9% | 172,633 | +15.1% | 0.03% | -22.7% |
| Q1 2016 | $1,997,000 | – | 149,931 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |